Shape 22 Experience

The Enhanced Liver Fibrosis (ELF™) Test

Enhanced Liver Fibrosis (ELF) Test Kit

Shortly after the only NASH blood test to be granted De Novo marketing authorization by the FDA in 2021, we are excited to announce that the ELF Test* is now included in the 2022 AACE NAFLD Clinical Practice Guidelines to help stratify NASH patients most at risk for progression to cirrhosis.

The Enhanced Liver Fibrosis (ELF) test

Because of the increasing disease burden,
lack of appropriate noninvasive testing
options is a major concern.

Assessment of liver fibrosis has traditionally relied on costly and invasive liver biopsy that requires a specialist, may not be representative of the amount of fibrosis, and carries a risk of life-threatening complications.​ Due to these limitations, biopsy is typically used sparingly.

Liber Fibrosis hotspot image

    Dr. Arun Sanyal discusses why risk-stratification of NASH patients is so important.

    In this video Dr. Arun Sanyal, Director of the Stravitz-Sanyal Institute for Liver Disease and Metabolic Health, VCU, discusses why risk-stratification of NASH patients is so important.

    ELF Test Guide - Teaser

    The Enhanced Liver Fibrosis Test Guide

    • The ELF Test is the first routine, standardized, direct-biomarker panel for prognostic risk assessment in patients with advanced fibrosis due to NASH.
    • ELF is the first and only in vitro diagnostic to be granted De Novo marketing authorization by the FDA for prognosis of patients with advanced fibrosis due to NASH.
    • The widely studied ELF Test can assess active, dynamic fibrosis rather than the damage it has caused. This allows the ELF Test to be used as a prognostic marker.
    1
    2
    3
    4